ReviewInternational journal of nanomedicine2022
Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.
Review in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- Smart Theranostic Nanoplatforms in Oral Squamous Cell Carcinoma: Integrating Diagnosis, Targeted Therapy and Synergistic Photothermal/Photodynamic Approaches.International journal of molecular sciences · 2026Review
- EphA2/SHP2/SOX8 Axis: A Novel Target for Regulation of Migration and Cetuximab Treatment Sensitivity in Oral Squamous Cell Carcinoma.Molecular carcinogenesis · 2026Article
- Sphingosine kinase 1 is dysregulated via hypoxia-inducible factor 1α in oral squamous cell carcinoma.The Indian journal of medical research · 2026Article
- Expression of the immune checkpoint CD137/CD137L in oral squamous cell carcinoma (OSCC) and association with histopathological parameters.Virchows Archiv : an international journal of pathology · 2026Article
- CXCL8 Drives MMP1 Upregulation and Promotes Metastatic Progression in Oral Cancer Through CXCR1/2-Mediated JAK1/STAT3 Activation.International journal of biological sciences · 2026Article
- Emotional distress is associated with neuroendocrine-immune remodeling and less favorable neoadjuvant immunotherapy outcomes in oral squamous cell carcinoma.Frontiers in immunology · 2026Article
- Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma.Frontiers in oncology · 2026Review
- Functional tongue reconstruction using innervated TDAP versus ALT free flaps: a retrospective paired-cohort study.Head & face medicine · 2025Observational
- Development of a cancer metastasis-associated risk model via multi-machine-learning algorithms for prognostic risk evaluation and clinical application in oral squamous cell carcinoma.Journal of translational medicine · 2025Article
- Clinicopathological and prognostic implications of OPMDs in oral squamous cell carcinoma: a 17-Year retrospective cohort study.BMC oral health · 2025Article
- Applications of nanomaterials in head and neck squamous cell carcinoma: current progress and perspectives.Discover nano · 2025Review
- Transcriptional reprogramming in oral squamous cell carcinoma.Scientific reports · 2025Article
- Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations.Cell biology and toxicology · 2025Review
- Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer.Polymers · 2025Review
- Article
- WGCNA and ferroptosis genes in OSCC: unraveling prognostic biomarkers and therapeutic targets.Discover oncology · 2025Article
- Exploring the role of oral bacteria in oral cancer: a narrative review.Discover oncology · 2025Review
- Hydrogen peroxide and cisplatin regulate the ROS/PKM2 pathway to affect the growth of cancer.American journal of cancer research · 2025Article
- Regulating Lipid MetabolismRecent patents on anti-cancer drug discovery · 2025Article
- BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumor in the head and neck, with a poor prognosis mainly due to recurrence and metastasis. Classical treatment modalities for OSCC like surgery and radiotherapy have difficulties in dealing with metastatic tumors, and together with chemotherapy, they have major problems related to non-specific cell death. Molecular targeted therapies offer solutions to these problems through not only potentially maximizing the anticancer efficacy but also minimizing the treatment-related toxicity. Among them, the receptor-mediated targeted delivery of anticancer therapeutics remains the most promising one. As OSCC exhibits a heterogeneous nature, selecting the appropriate receptors for targeting is the prerequisite. Hence, we reviewed the OSCC-associated receptors previously used in targeted therapy, focused on their biochemical characteristics and expression patterns, and discussed the application potential in personalized targeted therapy of OSCC. We hope that a better comprehension of this subject will help to provide the fundamental information for OSCC personalized therapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.